In Utero Corticosteroid Exposure Not Detrimental to Offspring Neurodevelopment
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 26, 2023 -- In utero exposure to corticosteroids and β2-adrenergic agonists appears to not be associated with most offspring neurodevelopmental outcomes, according to a study published online Oct. 24 in JAMA Network Open.
Abir Nagata, Ph.D., from Osaka University in Japan, and colleagues examined the association between timing of in utero exposure to corticosteroids and beta (β)2-adrenergic agonists and offspring neurodevelopmental milestones during the first three years of life using data from the ongoing Japan Environment and Children's Study. A total of 91,460 mother-offspring pairs were analyzed. Overall, 0.4, 1.0, and 0.6 percent of offspring were exposed to corticosteroids in early, mid-to-late, and both stages of pregnancy, respectively, and 0.2, 0.4, and 0.2 percent were exposed to β2-adrenergic agonists.
The researchers observed no association for corticosteroid exposure during early, mid-to-late, and both stages of pregnancy with any of the five neurodevelopmental milestones. Furthermore, no association was seen for β2-adrenergic agonist exposure during early pregnancy with any of the milestones. β2-adrenergic agonist exposure during mid-to-late pregnancy was associated with delayed personal-social skills (adjusted odds ratio, 1.48).
"Despite the study's limitations and its low power, these findings suggest that corticosteroids and β2-adrenergic agonists could be considered safe for use by pregnant individuals with asthma and safe for the neurodevelopment of their offspring," the authors write. "Additionally, the findings may inform choices regarding the management of maternal asthma during pregnancy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Clinical Response Seen for Patients With Severe Asthma Initiating Biologics
FRIDAY, June 28, 2024 -- Patients with severe asthma initiating biologics exhibit clinical responses and super-responses, but 40 to 50 percent do not meet response criteria...
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
NT-proBNP, IL-1RL Can Identify High-Risk Congenital Heart Disease in Neonates
MONDAY, June 24, 2024 -- Automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1) can identify high-risk congenital heart disease (CHD) in newborns...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.